This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines (NCT05048342), a na phase 3 study. The primary outcome is Number of Participants With Treatment Emergent Adverse Events.
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT05048342 |
| Phase | Phase 3 |
| Condition | Chronic Spontaneous Urticaria |
| Allocation | Not applicable (single group) |
| Design model | Single Group |
| Masking | None (open label) |
| Enrollment | 71 |
| Arms in the primary outcome | n/a |
| Lead sponsor | Novartis Pharmaceuticals |
| Results posted | Yes |
2. Clinical Question
Population
Adults in Japan with chronic spontaneous urticaria whose symptoms were inadequately controlled by H1-antihistamines. The study enrolled 71 participants. The registry describes the primary safety population as the Safety Set.
Intervention
Open-label oral remibrutinib, identified in the registry as LOU064, at 25 mg twice a day for 52 weeks. The study also included a post-treatment follow-up period of up to 4 weeks.
Comparator
There was no separate control group. The registry describes a single-group study and lists allocation as not applicable. The treatment was not masked.
Primary question
How many participants experienced treatment-emergent adverse events during treatment and the specified period after the last dose? The primary endpoint covers events beginning after the first dose, as well as certain pre-existing events that increased in severity during the defined observation period.
The registry frames the study as an evaluation of remibrutinib’s safety, tolerability and efficacy in adult Japanese patients with chronic spontaneous urticaria who remained symptomatic despite H1-antihistamine treatment at locally approved doses. Its principal endpoint is a safety count: the number of participants with treatment-emergent adverse events. The listed timeframe runs from baseline to 30 days after the last dose, with assessment described as lasting up to approximately 56 weeks.
Several secondary outcomes concern disease activity and quality of life. They include changes in weekly urticaria activity, itch severity and hives severity scores, and the number of participants reaching specified disease-control or quality-of-life thresholds. These outcomes are listed for specified study weeks, but their numerical results are not reported in the registry record summarized for this study.
Because there is no control group, the central question is descriptive: what adverse events and clinical outcomes were recorded among participants receiving the study treatment? The design does not directly estimate a difference between remibrutinib and another treatment or a control condition.
3. Trial Design
This was a Phase 3, multicenter, open-label, single-group study of remibrutinib (LOU064) in adult Japanese patients with chronic spontaneous urticaria inadequately controlled by H1-antihistamines. The registry lists 71 enrolled participants. The listed intervention was oral remibrutinib 25 mg twice a day for 52 weeks, followed by a post-treatment follow-up period of up to 4 weeks.
Allocation is recorded as not applicable, consistent with the registry’s single-group model. Masking is listed as none. Participants and study personnel therefore were not described as blinded to treatment assignment; there was no separate assignment to a control treatment. This design can document outcomes observed during treatment and follow-up, but it does not create a concurrent comparison group.
The study start date is 2022-01-15, the primary completion date is 2023-12-08, and the registry status is completed. These dates describe the recorded study timeline; they do not establish when individual participants began or ended treatment.
The primary outcome is the number of participants with treatment-emergent adverse events in the Safety Set. The registry defines the event window as beginning after the first study dose and continuing until 30 days after the last dose. An event already present before treatment could also qualify if its severity increased within that period. The outcome description says the assessment extended up to approximately 56 weeks.
The registry lists ten outcome measures, including secondary measures of urticaria activity, itch, hives, disease control and dermatology-related quality of life. The numerical results for these outcomes are not reported in the registry record. A detailed statistical analysis plan, including specified modeling choices or rules for handling missing data, is also not reported in the registry record.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Overall Study
| Stage | LOU064 25 mg b.i.d. |
|---|---|
| STARTED | 71 |
| COMPLETED | 68 |
| NOT COMPLETED | 3 |
Reasons for not completing this period:
| Reason | LOU064 25 mg b.i.d. |
|---|---|
| Adverse Event | 1 |
| Subject decision | 2 |
Analysis population for the primary outcome, as defined in the registry: Safety Set (SAF)
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
| Characteristic | Unit | LOU064 25 mg b.i.d. |
|---|---|---|
| Participants analysed | 71 | |
| Age, Continuous | Years | 43.5 (SD 12.52) |
| Age, Customized: >= 18 and < 65 years | Participants | 66 |
| Age, Customized: >= 65 and < 85 years | Participants | 5 |
| Sex: Female, Male: Female | Participants | 54 |
| Sex: Female, Male: Male | Participants | 17 |
| Race/Ethnicity, Customized: Asian | Participants | 71 |
6. Primary Endpoint
The registry lists the primary outcome as Number of Participants With Treatment Emergent Adverse Events, measured over Baseline up to 30 days after last dose of study medication, assessed up to approximately 56 weeks.
| Element | Registry entry |
|---|---|
| Result type | Count Of Participants |
| Measure of spread | not applicable |
| Unit | Participants |
| Endpoint classification | Binary Endpoint |
The primary endpoint counts participants with treatment-emergent adverse events. It is not a count of every event: a participant may experience more than one event, while the endpoint counts whether a participant had an event meeting the definition. The registry defines treatment-emergent events as those that start after the first dose and continue through 30 days after the last treatment dose. An event present before the first dose may qualify if its severity increases during that period.
Adverse events are unfavorable or unintended medical occurrences after written informed consent. The registry notes that an event may or may not be temporally or causally associated with the study medication. Thus, the endpoint records events within a specified observation window; it does not by itself establish that treatment caused them.
This kind of endpoint is used to describe the safety experience observed during a study. A participant count provides a straightforward summary of how many people had at least one qualifying event in the defined population and period. It does not convey the full event burden: event types, severity, timing, duration and recurrence require separate information.
The registry identifies the Safety Set as the endpoint population and reports the timeframe as baseline to 30 days after the last dose, assessed up to approximately 56 weeks. It does not report the primary endpoint result in the record, so the number of participants meeting the endpoint cannot be stated from that record.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The registry describes a completed, open-label study in a specific population: adult Japanese patients with chronic spontaneous urticaria inadequately controlled by H1-antihistamines. The design followed a single group receiving remibrutinib rather than comparing treatment groups. The recorded enrollment was 71. These features define the setting for interpreting the reported safety counts and limit what can be concluded about comparative effects.
For the primary endpoint, the registry gives the definition, observation window and analysis population, but does not report the primary endpoint result. The absence of that result in the registry record means the primary safety outcome cannot be quantified from the available record. It should not be read as evidence that no treatment-emergent adverse events occurred. The separate adverse-event figures report 3 participants with serious adverse events and 53 with other adverse events, with 71 at risk for each category. The record also lists 0 deaths. The meaning of these figures is descriptive, and the categories should not be combined into a new total.
The listed serious-event terms are Meniere's disease, Epiretinal membrane and Rhegmatogenous retinal detachment, each recorded as 1.4%. Those entries describe the terms highlighted in the registry; they do not provide a complete account of each participant’s clinical course, event timing, or possible relationship to treatment. The registry’s general adverse-event definition explicitly allows that an event may or may not be causally associated with the investigational product.
In a single-group study, an observed outcome has no concurrent control-group outcome against which to assess what might have happened under another treatment or without study treatment. Changes in symptoms over time may be described, but the design alone cannot isolate treatment effects from other influences, such as the natural course of the condition or changes in measurement. No numerical results for the listed secondary outcomes are reported in the registry record, so no conclusion about their observed magnitude or precision can be drawn from those entries.
Precision also cannot be assessed for the primary endpoint from the registry record because its result and an uncertainty interval are not reported. In general, a confidence interval communicates the range of values compatible with the data under the method used; it does not remove limitations in study design or establish causation. The registry record does not report an interval for this endpoint.
The study’s completion status indicates that the registry marks it completed; it does not substitute for an outcome estimate. Interpretation should therefore stay close to the information recorded: a single-group, open-label safety and efficacy study, with adverse-event counts available but the primary endpoint result and secondary outcome results not reported in the registry record.
9. Statistical Methods Explained
Statistical methods describe how study observations are summarized or compared and how uncertainty is represented. In general, the appropriate method depends on the outcome type, study design, analysis population and assumptions. The registry record does not report a detailed statistical analysis plan for this study, so specific methods beyond the endpoint definitions and recorded counts should not be assumed.
What does a participant count mean?
The primary outcome is a count of participants who experienced at least one treatment-emergent adverse event, rather than a count of all events. This distinction matters because a participant can have repeated events or events in different categories. Participant-level counts answer how many people had an event meeting the definition; event-level counts answer how many events occurred. They are not interchangeable. The registry identifies the Safety Set as the population for the primary endpoint.
For this endpoint, an event must fall within the registry’s treatment-emergent definition. Events starting after the first dose qualify if they occur within the stated period through 30 days after the last dose. A pre-existing event may qualify if it becomes more severe during that period. These rules set the scope of the count. They do not establish that an event was caused by the study medication.
Why does the single-group design matter?
A randomized comparison can estimate a difference between groups under the conditions of the trial. This study is recorded as single-group, with allocation not applicable and no masking. Its observed counts and outcomes therefore describe the participants receiving the intervention; they do not directly measure a treatment-versus-control contrast. General statistical caution: without a concurrent control, changes over time can reflect factors other than treatment, and a numerical association between treatment exposure and an outcome does not by itself establish causation.
Open-label conduct can also matter when outcomes involve judgments or participant reports. Knowledge of treatment may influence expectations, reporting or assessment. That is a general design consideration, not evidence that such influence occurred in this study. The registry does not report masking, and lists it as none.
How should uncertainty be understood?
In general, an estimate based on a sample is subject to sampling variability. A confidence interval is a range calculated using a specified statistical method to express uncertainty around an estimate. Its width depends on the data and method; a narrower interval generally indicates greater precision for that estimate. An interval does not account automatically for bias, confounding, incomplete outcome reporting or limits to generalizability. No confidence interval for the primary endpoint is reported in the registry record.
When event counts are small, estimates can be imprecise. General explanation: a small count may be compatible with a broad range of underlying event rates, so the count alone should not be treated as a precise estimate of risk. This study’s registry record does not provide an interval for the serious-event count. The reported counts should therefore be read as observed descriptive data, not as definitive estimates of event frequency in a broader population.
What do planning calculations represent?
General explanation: a sample-size calculation asks how much information a hypothetical study might need to detect a specified effect under stated assumptions. It is not a measure of what the completed study actually had the power to detect. Sample-size illustrations based on an observed effect are retrospective planning exercises, not observed power and not proof that an effect is real. Their assumptions can include significance level, allocation, statistical approximation and the fraction of an effect targeted.
The registry’s accompanying planning assumptions describe a two-arm, equal-allocation illustration and specify that the calculation is based on an observed effect. That illustration is not the design recorded for this single-group study and should not be interpreted as a description of the trial’s original sample-size rationale. The protocol’s sample-size justification is not reported in the registry record. No trial-specific interim analysis plan is reported either.
For binary outcomes, general planning methods often depend on the assumed event probability and the difference one aims to detect. For continuous outcomes, planning may depend on the expected mean difference and variability. For time-to-event outcomes, the number and timing of events can be central. These are general principles; the registry record does not report a full analysis plan that would identify methods used for each listed outcome.
Why can over-dispersion matter?
General explanation: over-dispersion occurs when observed variability is greater than a model assumes. If it is ignored, standard errors can be too small and uncertainty intervals too narrow. This issue is relevant to some count-data models, but the primary endpoint is defined as a number of participants with an event. The registry record does not identify a model for that endpoint, so no claim can be made that an over-dispersion adjustment was used or required.
10. Multiplicity, Missing Data and Analysis Populations
The registry lists ten outcome measures, including the primary adverse-event count and secondary measures of urticaria activity, itch, hives, disease control and quality of life. When a study assesses multiple outcomes or multiple time points, there can be more opportunities for apparently notable results by chance. General statistical practice may address this through prespecified outcome hierarchies, adjusted significance thresholds or a clearly descriptive interpretation. The registry record does not report whether any multiplicity adjustment was planned or applied, so the handling of multiple comparisons is not reported in the registry record.
The registry lists no analysis entries. It also does not report a detailed statistical analysis plan, including how missing outcome data were handled, whether any sensitivity analyses were prespecified, or whether covariate adjustment was planned. These details matter because different missing-data assumptions or analytic choices can affect estimates and their uncertainty. They should not be inferred from the endpoint names or from the study’s completed status.
The primary endpoint identifies the Safety Set as its analysis population. The record does not provide additional population definitions for the secondary outcomes in the information summarized for this study, nor does it explain how participants with incomplete assessments were treated. Therefore, the extent and handling of missing data, and the analysis populations for outcomes other than the primary endpoint, are not reported in the registry record.
General interpretation: prespecification helps distinguish planned analyses from exploratory findings, while transparent reporting lets readers evaluate how exclusions and missing observations may affect results. Without those details, conclusions should remain limited to the outcomes and counts explicitly recorded.
11. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| LOU064 25 mg b.i.d. | 3 | 71 | 4.2% |
Deaths
| Arm | Deaths (participants affected of at risk) |
|---|---|
| LOU064 25 mg b.i.d. | 0 of 71 |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 5% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| LOU064 25 mg b.i.d. | 53 of 71 |
Most frequent serious adverse event terms
| Event term | Organ system | LOU064 25 mg b.i.d. |
|---|---|---|
| Meniere's disease | Ear and labyrinth disorders | 1 of 71 |
| Epiretinal membrane | Eye disorders | 1 of 71 |
| Rhegmatogenous retinal detachment | Eye disorders | 1 of 71 |
Most frequent non-serious adverse event terms
| Event term | Organ system | LOU064 25 mg b.i.d. |
|---|---|---|
| COVID-19 | Infections and infestations | 14 of 71 |
| Headache | Nervous system disorders | 9 of 71 |
| Nasopharyngitis | Infections and infestations | 7 of 71 |
| Dermatitis atopic | Skin and subcutaneous tissue disorders | 7 of 71 |
| Diarrhoea | Gastrointestinal disorders | 6 of 71 |
| Eczema | Skin and subcutaneous tissue disorders | 6 of 71 |
| Tonsillitis | Infections and infestations | 5 of 71 |
| Acne | Skin and subcutaneous tissue disorders | 5 of 71 |
| Pyrexia | General disorders | 4 of 71 |
| Cystitis | Infections and infestations | 4 of 71 |
Serious events with the highest arm-level rate: meniere's disease (1.4%), epiretinal membrane (1.4%), rhegmatogenous retinal detachment (1.4%).
The registry reports 3 participants with serious adverse events among 71 at risk in the LOU064 25 mg twice-a-day group. It reports 53 participants with other adverse events among 71 at risk, and 0 deaths. These figures describe participant counts in the listed categories; they do not indicate how many total events occurred, how long events lasted, or whether the same participant experienced multiple events. The categories should not be added together.
The listed serious-event terms are Meniere's disease, Epiretinal membrane and Rhegmatogenous retinal detachment, each reported as 1.4%. The registry’s listing of these terms does not show whether events were judged related to treatment. Its adverse-event definition states that events may or may not be temporally or causally associated with the investigational product. The record does not report further details about event onset, duration, severity beyond the serious classification, resolution or treatment attribution in the information.
These counts are descriptive observations from a single-group, open-label study. They do not provide a control-group comparison, and the registry does not report a confidence interval for the primary endpoint. They should not be interpreted as a comparative estimate of safety or as proof of causation.
12. What the Result Does, and Does Not, Mean
The registry record establishes that a completed Phase 3 study evaluated open-label remibrutinib in adult Japanese patients with chronic spontaneous urticaria inadequately controlled by H1-antihistamines. It records an enrollment of 71 and provides descriptive adverse-event information for the treatment group. In particular, it reports 3 participants with serious adverse events, 53 with other adverse events, and 0 deaths. These observations describe the recorded safety experience; they do not establish whether treatment caused any event.
The record does not report the numerical result for the primary endpoint, which is the number of participants with treatment-emergent adverse events. It also does not report numerical results for the listed secondary outcomes. As a result, the registry entries do not support a quantified conclusion about the primary endpoint or the magnitude of change in urticaria activity, itch, hives, disease control or quality of life. Missing result reporting should not be interpreted as a result of zero events or zero change.
The single-group design does not provide a concurrent control outcome. Consequently, the recorded data cannot directly show how outcomes compare with another treatment or with no study treatment. The open-label design also means that participants and study personnel were not masked, as recorded by the registry. General design considerations such as expectation effects and changes in assessment may be relevant, but the record does not establish that they affected the observations.
The study’s population and treatment schedule also define the scope of the evidence. The findings concern the enrolled adult Japanese population described in the registry and the specified course of remibrutinib with follow-up. The record alone does not show how results would apply to other populations or treatment settings. No medical recommendation follows from these registry entries; the statistical interpretation is limited to what the recorded design and reported outcomes can support.
13. Why This Trial Matters Statistically
This study is statistically informative as an example of how to interpret a completed single-group safety study without turning descriptive observations into comparative claims. The registry specifies the population, treatment schedule, outcome definition and Safety Set for the primary endpoint. These details establish what was intended to be measured and over what period, even though the primary endpoint result itself is not reported in the registry record.
The distinction between an event count and a participant count is important for safety interpretation. A participant-level measure records whether a person experienced at least one qualifying event; it does not capture every event or its duration. The serious-event counts and highlighted terms offer some descriptive information, but they cannot answer questions about causality or comparative risk without further context and a suitable comparison.
The study also illustrates why design and reporting must be considered together. A single-group, open-label study can document outcomes during treatment, but it cannot directly estimate a treatment-group difference against a concurrent control. In addition, missing numerical results for the primary and secondary outcomes restrict how far readers can go beyond describing the study’s design and recorded adverse-event information.
Finally, the registry’s planning assumptions should be distinguished from the trial’s actual design. A hypothetical calculation based on an observed effect is not the same as a prospective sample-size justification, and it is not observed power. The protocol’s rationale and detailed statistical plan are not reported in the registry record. Keeping these distinctions clear helps prevent planning illustrations, descriptive counts and unreported analyses from being treated as interchangeable evidence.
14. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The main limitation for statistical interpretation is incomplete outcome reporting in the registry record. Although the primary endpoint is defined, its numerical result is not reported. Numerical results for the listed secondary outcomes are also not reported. This prevents assessment of their observed magnitudes and precision from this record.
The single-group design provides no concurrent control comparison, and the study is open-label. Observed outcomes therefore cannot be interpreted as a direct estimate of a difference versus another treatment. Without a comparison group, the registry record also cannot separate treatment-associated changes from other influences over time. This is a design limitation, not a claim that any particular influence affected the study.
The registry gives adverse-event participant counts and selected serious-event terms, but does not provide a confidence interval for the primary endpoint in the record. The reported counts do not give a full account of event timing, recurrence, duration, resolution or treatment attribution. The registry’s definition allows events that may or may not be causally associated with the study medication.
The detailed statistical analysis plan is not reported in the registry record. Specific approaches to multiplicity, missing data, sensitivity analysis and secondary-outcome analysis therefore cannot be evaluated. The record identifies the Safety Set for the primary endpoint but does not state further analysis-population details for the outcomes listed.
Finally, the study concerns adult Japanese patients with chronic spontaneous urticaria inadequately controlled by H1-antihistamines and a specified 52-week treatment schedule. The extent to which its observations apply beyond that population and setting is not established by the registry record.
15. Related Tutorials
16. Related Statistical Calculators
17. Sources
- ClinicalTrials.gov: A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines — NCT05048342.
- Registry record last updated 2025-04-08; status last verified 2025-04.
- Results first posted 2024-11-22.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
18. Record Summary
NCT05048342 is a completed Phase 3, multicenter, open-label, single-group study of oral remibrutinib (LOU064) in adult Japanese patients with chronic spontaneous urticaria inadequately controlled by H1-antihistamines. The registry lists enrollment of 71, treatment with 25 mg twice a day for 52 weeks, and follow-up of up to 4 weeks. The study start date is 2022-01-15 and the primary completion date is 2023-12-08.
The primary endpoint counts participants with treatment-emergent adverse events in the Safety Set. Its result is not reported in the registry record. The adverse-event entries report 3 participants with serious adverse events, 53 with other adverse events and 0 deaths; three serious-event terms are listed at 1.4% each. Numerical results for the listed secondary outcomes, a detailed statistical analysis plan and the protocol’s sample-size justification are not reported in the registry record. The single-group design supports descriptive interpretation, not a concurrent treatment comparison.